About Raptor
Raptor is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. We focus on underserved patient populations where we can have the greatest potential impact.
- Efficient: Raptor has built a robust and diversified product portfolio with great efficiency. In less than 3 years and $15 million, Raptor has built a product pipeline that may advance therapeutic options for 8 different indications and includes potential for both product launch and partnering revenue within the next 2 years.
- Collaborative: Raptor has a track record of successful acquisitions and collaborations. We will continue to collaborate with academic and commercial partners in order to advance patient care. Since our inception in late 2005, Raptor has completed 5 product candidate and technology acquisitions.
- Experienced: Our management team consists of repeat entrepreneurs with the experience to build a successful company. They have been involved in co-founding 5 companies including BioMarin Pharmaceutical, a fully integrated international biopharmaceutical company with a multi-billion dollar market capitalization.
Clinical development programs
Currently, Raptor is involved in clinical development of DR Cysteamine and Convivia™.
We are developing DR Cysteamine for the potential treatment of:
We are developing Convivia™ for the potential treatment of aldehyde dehydrogenase (ALDH2) deficiency.
Preclinical program
In our preclinical program, Raptor is bioengineering novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTide™, WntTide™ and NeuroTrans™.